VRDN Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2024-03-28 | Fairmount Funds Management LLC | director, 10 percent owner: | 1,845,813 | J-Other | A | 5,859 | 0.00 | 0.00 |
| 2024-03-28 | Fairmount Funds Management LLC | director, 10 percent owner: | 133,191 | J-Other | A | 21,999 | 0.00 | 0.00 |
| 2024-03-28 | Fairmount Funds Management LLC | director, 10 percent owner: | 0 | J-Other | D | 5,859 | 0.00 | 0.00 |
| 2024-03-28 | Fairmount Funds Management LLC | director, 10 percent owner: | 0 | J-Other | D | 21,999 | 0.00 | 0.00 |
| 2024-02-12 | Tousignant Jennifer | 0 | 0 | 0.00 | 0.00 | |||
| 2024-02-12 | Tousignant Jennifer | officer: Chief Legal Officer | 290,000 | A-Award | A | 290,000 | 19.68 | 5,707,200.00 |
| 2024-02-05 | Ciulla Thomas | officer: Chief Medical Officer | 50,000 | A-Award | A | 50,000 | 18.70 | 935,000.00 |
| 2024-01-22 | Fairmount Funds Management LLC | director, 10 percent owner, other: See Remarks | 1,839,954 | P-Purchase | A | 476,190 | 21.00 | 9,999,990.00 |
| 2024-01-03 | Ciulla Thomas | officer: Chief Medical Officer | 762 | D | 0 | 0.00 | 0.00 | |
| 2024-01-03 | Ciulla Thomas | officer: Chief Medical Officer | 0 | D | 50,000 | 28.22 | 1,411,000.00 | |
| 2024-01-03 | Ciulla Thomas | officer: Chief Medical Officer | 0 | D | 250,000 | 33.06 | 8,265,000.00 | |
| 2024-01-03 | Ciulla Thomas | officer: Chief Medical Officer | 0 | D | 270,000 | 13.76 | 3,715,200.00 | |
| 2023-11-10 | Harmon Seth | officer: See Remarks | 270,000 | A-Award | A | 270,000 | 13.76 | 3,715,200.00 |
| 2023-10-30 | Fairmount Funds Management LLC | director, 10 percent owner: | 48,463 | A-Award | A | 48,463 | 0.00 | 0.00 |
| 2023-10-30 | Beetham Thomas W. | 0 | 0 | 0.00 | 0.00 | |||
| 2023-10-30 | Beetham Thomas W. | officer: Chief Operating Officer | 474,400 | A-Award | A | 474,400 | 13.02 | 6,176,688.00 |
| 2023-10-30 | Mahoney Stephen F. | director, officer: President and CEO | 1,259,400 | A-Award | A | 1,259,400 | 13.02 | 16,397,388.00 |
| 2023-10-30 | Mahoney Stephen F. | 0 | 0 | 0.00 | 0.00 | |||
| 2023-09-21 | Gheuens Sarah | director | 40,000 | A-Award | A | 40,000 | 15.74 | 629,600.00 |
| 2023-09-21 | Gheuens Sarah | 0 | 0 | 0.00 | 0.00 | |||
| 2023-09-12 | Harmon Seth | officer: See Remarks | 0 | D | 175,000 | 24.50 | 4,287,500.00 | |
| 2023-06-15 | Meisner Lara | officer: Chief Legal Officer | 37,481 | M-Exempt | D | 2,269 | 23.03 | 52,255.00 |
| 2023-06-16 | Meisner Lara | officer: Chief Legal Officer | 37,453 | M-Exempt | D | 28 | 23.03 | 644.80 |
| 2023-06-15 | Meisner Lara | officer: Chief Legal Officer | 32,240 | M-Exempt | A | 2,269 | 23.03 | 52,255.00 |
| 2023-06-16 | Meisner Lara | officer: Chief Legal Officer | 29,998 | M-Exempt | A | 27 | 23.03 | 621.80 |
| 2023-06-16 | Meisner Lara | officer: Chief Legal Officer | 29,971 | S-Sale | D | 27 | 28.35 | 765.50 |
| 2023-06-15 | Meisner Lara | officer: Chief Legal Officer | 29,971 | S-Sale | D | 2,269 | 28.02 | 63,577.00 |
| 2023-06-14 | Harwin Peter Evan | director | 20,000 | A-Award | A | 20,000 | 27.67 | 553,400.00 |
| 2023-06-14 | Moses Jennifer K. | director | 20,000 | A-Award | A | 20,000 | 27.67 | 553,400.00 |
| 2023-06-14 | Kiselak Tomas | director | 20,000 | A-Award | A | 20,000 | 27.67 | 553,400.00 |
| 2023-06-14 | Morris Arlene | director | 20,000 | A-Award | A | 20,000 | 27.67 | 553,400.00 |
| 2023-06-05 | Meisner Lara | officer: Chief Legal Officer | 89,501 | M-Exempt | D | 499 | 18.51 | 9,236.00 |
| 2023-06-06 | Meisner Lara | officer: Chief Legal Officer | 84,375 | M-Exempt | D | 5,126 | 18.51 | 94,882.00 |
| 2023-06-06 | Meisner Lara | officer: Chief Legal Officer | 35,097 | M-Exempt | A | 5,126 | 18.51 | 94,882.00 |
| 2023-06-02 | Meisner Lara | officer: Chief Legal Officer | 31,846 | M-Exempt | A | 1,875 | 14.00 | 26,250.00 |
| 2023-06-05 | Meisner Lara | officer: Chief Legal Officer | 30,470 | M-Exempt | A | 499 | 18.51 | 9,236.00 |
| 2023-06-05 | Meisner Lara | officer: Chief Legal Officer | 29,971 | S-Sale | D | 499 | 25.03 | 12,490.00 |
| 2023-06-06 | Meisner Lara | officer: Chief Legal Officer | 29,971 | S-Sale | D | 5,126 | 25.02 | 128,253.00 |
| 2023-06-02 | Meisner Lara | officer: Chief Legal Officer | 29,971 | S-Sale | D | 1,875 | 24.21 | 45,394.00 |
| 2023-06-02 | Meisner Lara | officer: Chief Legal Officer | 18,128 | M-Exempt | D | 1,875 | 14.00 | 26,250.00 |
| 2023-04-12 | Myers Scott Dunseth | director, officer: Chief Executive Officer | 259,500 | P-Purchase | A | 4,000 | 25.37 | 101,479.00 |
| 2023-03-13 | Myers Scott Dunseth | 255,500 | P-Purchase | A | 5,500 | 29.15 | 160,324.00 | |
| 2023-03-09 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 29,971 | 29.07 | 871,257.00 |
| 2023-02-08 | Katz Barrett | officer: Chief Medical Officer | 108,000 | A-Award | A | 108,000 | 34.20 | 3,693,600.00 |
| 2023-02-08 | Melvin Carrie | officer: COO | 54,000 | A-Award | A | 54,000 | 34.20 | 1,846,800.00 |
| 2023-02-08 | Humer Kristian | officer: CFO and CBO | 108,000 | A-Award | A | 108,000 | 34.20 | 3,693,600.00 |
| 2023-02-08 | Meisner Lara | officer: General Counsel and Secretary | 108,000 | A-Award | A | 108,000 | 34.20 | 3,693,600.00 |
| 2023-02-06 | Myers Scott Dunseth | director, officer: Chief Executive Officer | 1,000,000 | A-Award | A | 1,000,000 | 35.80 | 35,800,000.00 |
| 2023-02-06 | Myers Scott Dunseth | director, officer: Chief Executive Officer | 250,000 | A-Award | A | 250,000 | 0.00 | 0.00 |
| 2023-02-06 | Myers Scott Dunseth | director, officer: Chief Executive Officer | 0 | 0 | 0.00 | 0.00 | ||
| 2023-02-02 | Violin Jonathan | director, officer: Chief Executive Officer | 530,905 | M-Exempt | A | 50,000 | 0.15 | 7,500.00 |
| 2023-02-02 | Violin Jonathan | director, officer: Chief Executive Officer | 480,905 | S-Sale | D | 50,000 | 36.80 | 1,840,000.00 |
| 2023-02-02 | Violin Jonathan | director, officer: Chief Executive Officer | 239,205 | M-Exempt | D | 50,000 | 0.15 | 7,500.00 |
| 2023-02-02 | Violin Jonathan | director, officer: Chief Executive Officer | 430,905 | S-Sale | D | 50,000 | 36.80 | 1,840,000.00 |
| 2023-01-23 | Meisner Lara | officer: General Counsel and Secretary | 39,750 | M-Exempt | D | 4,971 | 0.00 | 0.00 |
| 2023-01-23 | Meisner Lara | officer: General Counsel and Secretary | 20,003 | M-Exempt | D | 1,872 | 0.00 | 0.00 |
| 2023-01-23 | Meisner Lara | officer: General Counsel and Secretary | 6,843 | M-Exempt | A | 1,872 | 14.00 | 26,208.00 |
| 2023-01-23 | Meisner Lara | officer: General Counsel and Secretary | 4,971 | M-Exempt | A | 4,971 | 23.03 | 114,482.00 |
| 2023-01-23 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 6,843 | 35.66 | 244,021.00 |
| 2023-01-13 | Katz Barrett | officer: Chief Medical Officer | 291,853 | M-Exempt | D | 4,147 | 0.00 | 0.00 |
| 2023-01-17 | Katz Barrett | officer: Chief Medical Officer | 267,000 | M-Exempt | D | 24,853 | 0.00 | 0.00 |
| 2023-01-17 | Katz Barrett | officer: Chief Medical Officer | 24,853 | M-Exempt | A | 24,853 | 23.03 | 572,365.00 |
| 2023-01-13 | Katz Barrett | officer: Chief Medical Officer | 4,147 | M-Exempt | A | 4,147 | 23.03 | 95,505.00 |
| 2023-01-17 | Katz Barrett | officer: Chief Medical Officer | 0 | S-Sale | D | 24,853 | 37.21 | 924,780.00 |
| 2023-01-09 | Katz Barrett | officer: Chief Medical Officer | 343,377 | M-Exempt | D | 12,623 | 0.00 | 0.00 |
| 2023-01-10 | Katz Barrett | officer: Chief Medical Officer | 296,000 | M-Exempt | D | 47,377 | 0.00 | 0.00 |
| 2023-01-10 | Katz Barrett | officer: Chief Medical Officer | 47,377 | M-Exempt | A | 47,377 | 23.03 | 1,091,092.00 |
| 2023-01-09 | Katz Barrett | officer: Chief Medical Officer | 12,623 | M-Exempt | A | 12,623 | 23.03 | 290,708.00 |
| 2023-01-10 | Katz Barrett | officer: Chief Medical Officer | 0 | S-Sale | D | 47,377 | 35.30 | 1,672,408.00 |
| 2022-12-20 | Meisner Lara | officer: General Counsel and Secretary | 61,047 | M-Exempt | D | 600 | 0.00 | 0.00 |
| 2022-12-21 | Meisner Lara | officer: General Counsel and Secretary | 44,721 | M-Exempt | D | 16,326 | 0.00 | 0.00 |
| 2022-12-21 | Meisner Lara | officer: General Counsel and Secretary | 16,326 | M-Exempt | A | 16,326 | 23.03 | 375,988.00 |
| 2022-12-20 | Meisner Lara | officer: General Counsel and Secretary | 600 | M-Exempt | A | 600 | 23.03 | 13,818.00 |
| 2022-12-21 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 16,326 | 29.19 | 476,556.00 |
| 2022-12-15 | Meisner Lara | officer: General Counsel and Secretary | 62,944 | M-Exempt | D | 300 | 0.00 | 0.00 |
| 2022-12-16 | Meisner Lara | officer: General Counsel and Secretary | 61,647 | M-Exempt | D | 1,297 | 0.00 | 0.00 |
| 2022-12-16 | Meisner Lara | officer: General Counsel and Secretary | 1,297 | M-Exempt | A | 1,297 | 23.03 | 29,870.00 |
| 2022-12-15 | Meisner Lara | officer: General Counsel and Secretary | 300 | M-Exempt | A | 300 | 23.03 | 6,909.00 |
| 2022-12-16 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 1,297 | 28.44 | 36,887.00 |
| 2022-12-12 | Meisner Lara | officer: General Counsel and Secretary | 78,900 | M-Exempt | D | 600 | 0.00 | 0.00 |
| 2022-12-14 | Meisner Lara | officer: General Counsel and Secretary | 63,244 | M-Exempt | D | 15,656 | 0.00 | 0.00 |
| 2022-12-14 | Meisner Lara | officer: General Counsel and Secretary | 15,656 | M-Exempt | A | 15,656 | 23.03 | 360,558.00 |
| 2022-12-12 | Meisner Lara | officer: General Counsel and Secretary | 600 | M-Exempt | A | 600 | 23.03 | 13,818.00 |
| 2022-12-14 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 15,656 | 28.12 | 440,247.00 |
| 2022-11-15 | Meisner Lara | officer: General Counsel and Secretary | 21,875 | M-Exempt | D | 8,125 | 0.00 | 0.00 |
| 2022-11-15 | Meisner Lara | officer: General Counsel and Secretary | 8,125 | M-Exempt | A | 8,125 | 14.00 | 113,750.00 |
| 2022-11-15 | Meisner Lara | officer: General Counsel and Secretary | 0 | S-Sale | D | 8,125 | 22.05 | 179,156.00 |
| 2022-08-17 | Fairmount Healthcare Fund II L.P. | director: | 1,363,764 | P-Purchase | A | 425,531 | 23.50 | 9,999,978.00 |
| 2022-06-21 | Melvin Carrie | officer: COO | 0 | D | 210,000 | 10.63 | 2,232,300.00 | |
| 2022-06-08 | Moses Jennifer K. | director: | 12,500 | A-Award | A | 12,500 | 0.00 | 0.00 |
| 2022-06-08 | Moses Jennifer K. | director | 12,500 | A-Award | A | 12,500 | 12.31 | 153,875.00 |
| 2022-06-08 | Kiselak Tomas | director: | 12,500 | A-Award | A | 12,500 | 0.00 | 0.00 |
| 2022-06-08 | Harwin Peter Evan | director: | 12,500 | A-Award | A | 12,500 | 0.00 | 0.00 |
| 2022-06-08 | Harwin Peter Evan | director | 12,500 | A-Award | A | 12,500 | 12.31 | 153,875.00 |
| 2022-06-08 | Morris Arlene | director: | 12,500 | A-Award | A | 12,500 | 0.00 | 0.00 |
| 2022-06-01 | Violin Jonathan | officer: Chief Executive Officer | 480,905 | S-Sale | D | 30,000 | 12.20 | 366,000.00 |
| 2022-05-02 | Violin Jonathan | officer: Chief Executive Officer | 510,905 | S-Sale | D | 30,000 | 13.04 | 391,200.00 |
| 2022-04-01 | Violin Jonathan | director, officer: Chief Executive Officer | 544,505 | S-Sale | D | 26,400 | 18.92 | 499,488.00 |
| 2022-04-01 | Violin Jonathan | officer: Chief Executive Officer | 540,905 | S-Sale | D | 3,600 | 18.93 | 68,148.00 |
| 2022-03-01 | Violin Jonathan | director, officer: Chief Executive Officer | 582,011 | S-Sale | D | 18,894 | 17.82 | 336,691.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
